Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases

Ahmad AlEnizi 1, Khaled AlSaeid 2, Adel Alawadhi 2, Eiman Hasan 3, Entesar H Husain 4, Ahmad AlFadhli 5, Aqeel Ghanem 5, Fatemah Abutiban 1, Yaser Ali 5, Adeeba Al-Herz 3, Khuloud Mohammed 6, Waleed Alkandari 6, Ali Aldei 3, Hebah Alhajeri 5, Ahmad Dehrab 7, Sawsan Hayat 5

Affiliations

13 May 2018

-

doi: 10.1155/2018/5217461

Abstract

People with IRD are at increased risk of infection, and in 2011 EULAR made general recommendations for vaccination in these patients. Global and European perspectives are important, but they cannot accurately reflect the individual situations of patients in different countries and regions. Based on our clinical experience and opinions, we have sought to tailor the original EULAR recommendations to include advice for vaccination with new agents approved in the intervening years-including the new class of targeted synthetic disease-modifying antirheumatic drugs. We have also considered the specific demographic needs of patients in local populations in the Gulf region. The resulting 16 recommendations are grouped into four main categories covering general vaccination guidelines and best-practice for all patients with IRD, followed by a set of recommended vaccines against specific pathogens. The last two categories include recommendations for certain patient subgroups with defined risks and for patients who wish to travel.

Figures

Figure 1 Recommendations for HBV screening and prophylaxis in patients to be administered with bDMARDs, tsDMARDs, or >7.5 mg/day prednisolone [29]. 1Treatment period is up until the patient becomes HBsAg negative in patients with chronic hepatitis B (liver disease), and antiviral treatment should continue 6–12 months after immunosuppressive and/or bDMARD treatment is completed in patients without liver disease (12 months for rituximab). 2If rituximab is to be administered, antiviral prophylaxis should be given, even if patients are negative for HBV DNA (−). 3HBV DNA is repeated once in 1–6 months (3 months on average). Figure reproduced with permission from the European Journal of Rheumatology.

Figure 1 Recommendations for HBV screening and prophylaxis in patients to be administered with bDMARDs, tsDMARDs, or >7.5 mg/day prednisolone [29]. 1Treatment period is up until the patient becomes HBsAg negative in patients with chronic hepatitis B (liver disease), and antiviral treatment should continue 6–12 months after immunosuppressive and/or bDMARD treatment is completed in patients without liver disease (12 months for rituximab). 2If rituximab is to be administered, antiviral prophylaxis should be given, even if patients are negative for HBV DNA (−). 3HBV DNA is repeated once in 1–6 months (3 months on average). Figure reproduced with permission from the European Journal of Rheumatology.

Box 1 Inflammatory rheumatic diseases [8].

Box 1 Inflammatory rheumatic diseases [8].

Box 2 Vaccine overview.

Box 2 Vaccine overview.

Similar articles

Recommendation for the Management of Spondyloarthritis Patients in Kuwait.

Ali Y, Abutiban F, Alawadhi A, AlDei A, Alenizi A, Alhajeri H, Al-Herz A, Alkandari W, Dehrab A, Hasan E, Hayat S, Ghanem A, Saleh K, Baraliakos X.Open Access Rheumatol. 2020 Aug 12;12:147-165. doi: 10.2147/OARRR.S246246. eCollection 2020.PMID: 32903931 Free PMC article.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.PMID: 31413005

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.PMID: 30212088 Free Books & Documents. Review.

Management of vaccination in rheumatic disease.

Wong PKK, Hanrahan P.Best Pract Res Clin Rheumatol. 2018 Dec;32(6):720-734. doi: 10.1016/j.berh.2019.03.006. Epub 2019 Apr 17.PMID: 31427051 Review.

Recommendations for Vaccination in Adult Patients with Systemic Inflammatory Rheumatic Diseases from the Portuguese Society of Rheumatology.

Cordeiro I, Duarte AC, Ferreira JF, Gonçalves MJ, Meirinhos T, Rocha TM, Romão VC, Sousa S, Guedes M, Conde M, Abreu C, Aleixo MJ, Santos MJ.Acta Reumatol Port. 2016 Apr-Jun;41(2):112-30.PMID: 27606471 English.

Cited by

Recommendation for the Management of Spondyloarthritis Patients in Kuwait.

Ali Y, Abutiban F, Alawadhi A, AlDei A, Alenizi A, Alhajeri H, Al-Herz A, Alkandari W, Dehrab A, Hasan E, Hayat S, Ghanem A, Saleh K, Baraliakos X.Open Access Rheumatol. 2020 Aug 12;12:147-165. doi: 10.2147/OARRR.S246246. eCollection 2020.PMID: 32903931 Free PMC article.

Vaccination coverage in Qatar: Benchmarking with global figures.

Al-Dahshan A, Hammoud H, Chehab M, Osman SRO.Qatar Med J. 2019 Jul 25;2019(1):4. doi: 10.5339/qmj.2019.4. eCollection 2019.PMID: 31384573 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Falagas M. E., Manta K. G., Betsi G. I., Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: A systematic review. 2007;26(5):663–670. doi: 10.1007/s10067-006-0441-9. - DOI - PubMed
  2.  
    1. Doran M. F., Crowson C. S., Pond G. R., O'Fallon W. M., Gabriel S. E. Frequency of infection in patients with rheumatoid arthritis compared with controls: A Population-Based Study. 2002;46(9):2287–2293. doi: 10.1002/art.10524. - DOI - PubMed
  3.  
    1. Wolfe F., Mitchell D. M., Sibley J. T., et al. The mortality of rheumatoid arthritis. 1994;37(4):481–494. doi: 10.1002/art.1780370408. - DOI - PubMed
  4.  
    1. Cervera R., Khamashta M. A., Font J. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. 2003;82(5):299–308. doi: 10.1097/01.md.0000091181.93122.55. - DOI - PubMed
  5.  
    1. Rahier J.-F., Moutschen M., van Gompel A., et al. Vaccinations in patients with immune-mediated inflammatory diseases. 2010;49(10):1815–1827. doi: 10.1093/rheumatology/keq183. - DOI - PMC - PubMed
  6.  
    1. Snydman D. R., Toussi S. S., Pan N., Walters H. M., Walsh T. J. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor- Inhibitors: Systematic review of the literature. 2013;57(9):1318–1330. doi: 10.1093/cid/cit489. - DOI - PMC - PubMed
  7.  
    1. Arvas A. Vaccination in patients with immunosuppression. 2014;49(3):181–185. doi: 10.5152/tpa.2014.2206. - DOI - PMC - PubMed
  8.  
    1. van Assen S., Agmon-Levin N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. 2011;70(3):414–422. doi: 10.1136/ard.2010.137216. - DOI - PubMed
  9.  
    1. Weiskopf D., Weinberger B., Grubeck-Loebenstein B. The aging of the immune system. 2009;22(11):1041–1050. doi: 10.1111/j.1432-2277.2009.00927.x. - DOI - PubMed
  10.  
    1. Weinberger B., Herndler-Brandstetter D., Schwanninger A., Weiskopf D., Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. 2008;46(7):1078–1084. doi: 10.1086/529197. - DOI - PubMed
  11.  
    1. Overturf G. D. Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis. 2000;106(2):367–376. doi: 10.1542/peds.106.2.367. - DOI - PubMed
  12.  
    1. Kuna. 2016, http://www.kuna.net.kw/ArticlePrintPage.aspx?id=1971118&language=en.
  13.  
    1. WHO. http://apps.who.int/immunization_monitoring/globalsummary/countries?coun....
  14.  
    1. Kuna. 2016, http://www.kuna.net.kw/ArticlePrintPage.aspx?id=2471349&language=en.
  15.  
    1. French G., Hill A. G. Kuwait: Urban and Medical Ecology. A Geomedical Study. https://books.google.com.kw/books?id=P2aSBAAAQBAJ&pg=PA113&lpg=P....
  16.  
    1. Al-Awadhi R., Chehadeh W., Kapila K. Prevalence of human papillomavirus among women with normal cervical cytology in Kuwait. 2011;83(3):453–460. doi: 10.1002/jmv.21981. - DOI - PubMed
  17.  
    1. Husain E. H., Barakat M., Al-Saleh M. Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013. 2015;8(5):441–447. doi: 10.1016/j.jiph.2015.01.009. - DOI - PubMed
  18.  
    1. Emadi S. A., Hammoudeh M., Mounir M., Mueller R. B., Wells A. F., Sarakbi H. A. An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions. 2017;45(2):733–743. doi: 10.1177/0300060516686872. - DOI - PMC - PubMed
  19.  
    1. Feldman C., Abdulkarim E., Alattar F., et al. Pneumococcal disease in the Arabian Gulf: Recognizing the challenge and moving toward a solution. 2013;6(6):401–409. doi: 10.1016/j.jiph.2013.06.004. - DOI - PubMed
  20.  
    1. Gautret P., Bauge M., Simon F., Benkouiten S., Parola P., Brouqui P. Pneumococcal vaccination and Hajj. 2011;15(10):p. e730. doi: 10.1016/j.ijid.2011.07.001. - DOI - PubMed
  21.  
    1. Al-Ghamdi S. M., Akbar H. O., Qari Y. A., Fathaldin O. A., Al-Rashed R. S. Pattern of admission to hospitals during muslim pilgrimage (Hajj) 2003;24(10):1073–1076. - PubMed
  22.  
    1. Madani T. A., Ghabrah T. M., Al-Hedaithy M. A., et al. Causes of hospitalization of pilgrims during the Hajj period of the Islamic year 1423 (2003) 2006;26(5):346–351. doi: 10.5144/0256-4947.2006.346. - DOI - PMC - PubMed
  23.  
    1. Baharoon S., Al-Jahdali H., Al Hashmi J., Memish Z. A., Ahmed Q. A. Severe sepsis and septic shock at the Hajj: Etiologies and outcomes. 2009;7(4):247–252. doi: 10.1016/j.tmaid.2008.09.002. - DOI - PubMed
  24.  
    1. Blank P. R., Schwenkglenks M., Szucs T. D. Disparities in influenza vaccination coverage rates by target group in five European countries: Trends over seven consecutive seasons. 2009;37(5):390–400. doi: 10.1007/s15010-009-8467-y. - DOI - PubMed
  25.  
    1. Abu-Gharbieh E., Fahmy S., Rasoo B. A., Khan S. Influenza vaccination: Healthcare workers attitude in three middle east countries. 2010;7(5):319–325. doi: 10.7150/ijms.7.319. - DOI - PMC - PubMed
  26.  
    1. Costello R., Winthrop K. L., Pye S. R., Brown B., Dixon W. G. Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: A retrospective cohort study using data from the clinical practice research datalink. 2016;11(4) doi: 10.1371/journal.pone.0153848.e0153848 - DOI - PMC - PubMed
  27.  
    1. Müller-Ladner C., Müller-Ladner U. Vaccination and inflammatory arthritis: Overview of current vaccines and recommended uses in rheumatology topical collection on infections and arthritis. 2013;15(6, article no. 330) doi: 10.1007/s11926-013-0330-6. - DOI - PubMed
  28.  
    1. Feuchtenberger M., Schäfer A., Nigg A. P., Kraus M. R. Hepatitis B serology in patients with rheumatic diseases. 2016;10:39–48. doi: 10.2174/1874312901610010039. - DOI - PMC - PubMed
  29.  
    1. Karadağ Ö., Kaşifoğlu T., Özer B., et al. Viral hepatitis screening guideline before biological drug use in rheumatic patients. 2016;3(1):25–28. doi: 10.5152/eurjrheum.2015.150072. - DOI - PMC - PubMed
  30.  
    1. Mori S., Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. 2015;21(36):10274–10289. doi: 10.3748/wjg.v21.i36.10274. - DOI - PMC - PubMed
  31.  
    1. Hoofnagle J. H. Reactivation of hepatitis B. 2009;49(supplement 5):S156–S165. doi: 10.1002/hep.22945. - DOI - PubMed
  32.  
    1. Shouval D., Shibolet O. Immunosuppression and HBV reactivation. 2013;33(2):167–177. doi: 10.1055/s-0033-1345722. - DOI - PubMed
  33.  
    1. Bessone F., Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. 2016;8(8):385–394. doi: 10.4254/wjh.v8.i8.385. - DOI - PMC - PubMed
  34.  
    1. Mast E. E., Margolis H. S., Fiore A. E., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. 2005;54(16):1–31. - PubMed
  35.  
    1. Mastroianni C. M., Lichtner M., Citton R., et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. 2011;17(34):3881–3887. doi: 10.3748/wjg.v17.i34.3881. - DOI - PMC - PubMed
  36.  
    1. Zycinska. K. Antibody response to inactivated subunit influenza vaccine in patients with Wegener’s granulomatosis. 2007;(supplement 5):819–828. (Pt 2) - PubMed
  37.  
    1. Guthridge. Herpes Zoster Vaccination in SLE: A pilot study of Immunogenicity. 2013;40(11) - PMC - PubMed
  38.  
    1. King S. M., Saunders E. F., Petric M., Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. 1996;17(4):633–636. - PubMed
  39.  
    1. Levin M. J., Gershon A. A., Weinberg A., Song L.-Y., Fentin T., Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. 2006;194(2):247–255. doi: 10.1086/505149. - DOI - PubMed
  40.  
    1. Bühler S., Eperon G., Ribi C., et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. 2015;145 doi: 10.4414/smw.2015.14159.14159 - DOI - PubMed
  41.  
    1. Russell A. F., Parrino J., Fisher C. L., et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. 2015;33(27):3129–3134. doi: 10.1016/j.vaccine.2015.04.090. - DOI - PubMed
  42.  
    1. Singh J. A., Saag K. G., Bridges L., Jr., et al. American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016;68:1–26.
  43.  
    1. Mori S., Ueki Y., Hirakata N., Oribe M., Hidaka T., Oishi K. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. 2012;71(12):2006–2010. doi: 10.1136/annrheumdis-2012-201950. - DOI - PMC - PubMed
  44.  
    1. Eisenberg R. A., Jawad A. F., Boyer J., et al. Rituximab-treated patients have a poor response to influenza vaccination. 2013;33(2):388–396. doi: 10.1007/s10875-012-9813-x. - DOI - PMC - PubMed
  45.  
    1. Kapetanovic M. C., Kristensen L.-E., Saxne T., Aktas T., Mörner A., Geborek P. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. 2014;16(1, article no. R2) doi: 10.1186/ar4427. - DOI - PMC - PubMed
  46.  
    1. Ribeiro A. C., Laurindo I. M., Guedes L. K., et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. 2013;65(3):476–480. doi: 10.1002/acr.21838. - DOI - PubMed
  47.  
    1. Adler S., Krivine A., Weix J., et al. Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study. 2012;51(4):695–700. doi: 10.1093/rheumatology/ker389.ker389 - DOI - PubMed
  48.  
    1. Tay L., Leon F., Vratsanos G., Raymond R., Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: A randomized, open-label, parallel group study in healthy subjects. 2007;9, article no. R38 doi: 10.1186/ar2174. - DOI - PMC - PubMed
  49.  
    1. Papadopoulou D., Sipsas N. V. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. 2014;34(2):151–163. doi: 10.1007/s00296-013-2907-9. - DOI - PubMed
  50.  
    1. Shearer W. T., Fleisher T. A., Buckley R. H., et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. 2014;133(4):961–966. doi: 10.1016/j.jaci.2013.11.043. - DOI - PMC - PubMed
  51.  
    1. Rubin L. G., Levin M. J., Ljungman P. Erratum: Executive summary: 2013 IDSA clinical practice guideline for vaccination of the immunocompromist host (Clinical Infectious Diseases (2014) 58 (309-318)) 2014;59(1):p. 144. doi: 10.1093/cid/ciu256. - DOI
  52.  
    1. Kroger A. T., Duchin J., Vázquez M. 2017. General best practice guidelines for immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
  53.  
    1. Kamboj M., Sepkowitz K. A. Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. 2007;28(6):702–707. doi: 10.1086/517952. - DOI - PubMed
  54.  
    1. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) 2011;60:1–64. - PubMed
  55.  
    1. Alten R., Bingham C. O., Cohen S. B., et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. 2016;17(1, article no. 231) doi: 10.1186/s12891-016-1082-z. - DOI - PMC - PubMed
  56.  
    1. Liao Z., Tang H., Xu X., Liang Y., Xiong Y., Ni J. Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis. 2016;11(2) doi: 10.1371/journal.pone.0147856.e0147856 - DOI - PMC - PubMed
  57.  
    1. Winthrop K. L., Silverfield J., Racewicz A., et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. 2016;75(4):687–695. doi: 10.1136/annrheumdis-2014-207191. - DOI - PMC - PubMed
  58.  
    1. Durusu Tanrıover M., Akar S., Turkcapar N., Karadag O., Ertenli I., Kiraz S. Vaccination recommendations for adult patients with rheumatic diseases. 2016;3(1):29–35. doi: 10.5152/eurjrheum.2016.16100. - DOI - PMC - PubMed
  59.  
    1. Fischer L., Gerstel P. F., Poncet A., et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases - A longitudinal study. 2015;17(1, article no. 151) doi: 10.1186/s13075-015-0663-9. - DOI - PMC - PubMed
  60.  
    1. Kuwaiti MOH. Schedule of Essential Vaccination by Age; State of Kuwait. 2008, https://www.e.gov.kw/sites/kgoEnglish/Pages/CitizensResidents/Health/Bas....
  61.  
    1. WHO. Global overview. 2016, http://global-report.worldhepatitisalliance.org/files/global_report/down.... - DOI
  62.  
    1. Cogman A. R., Chakravarty E. F. The case for Zostavax vaccination in systemic lupus erythematosus. 2013;31(36):3640–3643. doi: 10.1016/j.vaccine.2013.05.085. - DOI - PMC - PubMed
  63.  
    1. Glück T., Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. 2008;46(9):1459–1465. doi: 10.1086/587063. - DOI - PubMed
  64.  
    1. Lindsey S., Walker H. Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy. 2014
  65.  
    1. Arbeláez M. P., Nelson K. E., Muñoz A. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection. 2000;29(6):1085–1091. doi: 10.1093/ije/29.6.1085. - DOI - PubMed
  66.  
    1. Moraes-Fontes M. F., Antunes A. M., Gruner H., Riso N. Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal. 2016;2016 doi: 10.1155/2016/2845617.2845617 - DOI - PMC - PubMed
  67.  
    1. Grein I. H., Groot N., Lacerda M. I., Wulffraat N., Pileggi G. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. 2016;14(1) doi: 10.1186/s12969-016-0072-x. - DOI - PMC - PubMed
  68.  
    1. Feldman C. H., Kim S. C. Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake? 2014;13(8):931–934. doi: 10.1586/14760584.2014.930346. - DOI - PMC - PubMed
  69.  
    1. Schwartz B. S., Rosen J., Han P. V., et al. Immunocompromised travelers: Demographic characteristics, travel destinations, and pretravel health care from the u.s. global travepinet consortium. 2015;93(5):1110–1116. doi: 10.4269/ajtmh.15-0185. - DOI - PMC - PubMed
  70.  
    1. Shujaa A., Alhamid S. Health response to Hajj mass gathering from emergency perspective, narrative review. 2015;15(4):172–176. doi: 10.1016/j.tjem.2015.02.001. - DOI - PMC - PubMed

Page Navigation